BIOS Capital Management, LP
•CIK: 1813845•Filing: Q4 2025
**BIOS Capital Management, LP** is a focused, actively managed fund with $83M AUM, currently maintaining a concentrated portfolio of six positions. The strategy is heavily weighted toward biotechnology and life sciences, evidenced by the dominant $61.5M allocation to ACTU, representing over 74% of the reported holdings. Significant secondary positions include CGTX at $8.1M and IRD at $7.4M, indicating deep conviction in specific clinical-stage assets. This structure suggests a high-conviction, specialized approach within the biotech sector.
Total AUM
$82.6M
QoQ Performance
-7.1%
Positions
6
Top 10 Concentration
100.0%
Latest Filing
Q4 2025
Top Holdings Allocation
ACTU
CGTX
IRD
ACTU74.4%
CGTX9.8%
IRD9.0%
LTRN3.7%
RNTX2.4%
INAB0.7%
📈 Biggest Buys
INAB
IN8BIO INC
NEW
0.7% of portfolio
📉 Biggest Sells
LTRN
LANTERN PHARMA INC
-0.6%
3.7% of portfolio
Sector Breakdown
Other100.0%
🚪 Exited Positionssold since Q3 2025
—
IN8BIO INC
SOLD
$622.1K
Changes from Q3 2025
NEW1 new position
↓1 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024